The non-clinical reports suggest that a PAM inhibitor’s effectiveness in patients with BC would be enhanced when combined with a selective estrogen receptor degrader alone or also in combination with a CDK4/6 inhibitor57–59. This evidence concerns the gene ESR1 and breast cancer.